Download Files:

Sotorasib

SKU T8684-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 50 CAD through 2,288 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

2 mg 1 g 1 mg 1 mL * 10 mM (in DMSO)10 mg 100 mg 25 mg 5 mg 50 mg 500 mg

Clear

Products Details

Product Description

– Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib exhibits inhibitory activity against KRAS G12C mutant tumors.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T8684

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C30H30F2N6O3

Citations

– 1. Yang N, Fan Z, Sun S, et al.Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.European Journal of Medicinal Chemistry.2023: 115857. 2. Yun S D, Scott E, Moghadamchargari Z, et al.2′-Deoxy Guanosine Nucleotides Alter the Biochemical Properties of Ras.Biochemistry.2023 3. Wu L L, Jiang W M, Liu Z Y, et al.AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research.Discover Oncology.2023, 14(1): 91. 4. Guo Y, Tian J, Guo Y, et al.Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.Cell Reports.2023, 42(12). 5. Nokin M J, Mira A, Patrucco E, et al.RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.Nature Communications.2024, 15(1): 7554. 6. Bian Y, Shan G, Bi G, et al.Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis.Redox Biology.2024: 103361.

References

– Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223.

CAS Number

– 2296729-00-3

Molecular Weight

– C30H30F2N6O3

Compound Purity

– 0.9988

SMILES

– O=C1N=C(C=2C=C(F)C(=NC2N1C=3C(=NC=CC3C)C(C)C)C=4C(F)=CC=CC4O)N5CCN(C(=O)C=C)CC5C

Pathway

– GPCR/G Protein|||MAPK

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.